Agios Pharmaceuticals Inc. (AGIO)’s Financial Results Comparing With Strongbridge Biopharma plc (NASDAQ:SBBP)

We will be contrasting the differences between Agios Pharmaceuticals Inc. (NASDAQ:AGIO) and Strongbridge Biopharma plc (NASDAQ:SBBP) as far as dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Agios Pharmaceuticals Inc. 52 21.34 N/A -5.99 0.00
Strongbridge Biopharma plc 4 7.00 N/A 0.85 3.04

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Agios Pharmaceuticals Inc. and Strongbridge Biopharma plc.

Profitability

Table 2 provides Agios Pharmaceuticals Inc. and Strongbridge Biopharma plc’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Agios Pharmaceuticals Inc. 0.00% -48.2% -38.6%
Strongbridge Biopharma plc 0.00% 79.3% 27.2%

Volatility & Risk

Agios Pharmaceuticals Inc. has a 2.17 beta, while its volatility is 117.00%, thus making it more volatile than Standard & Poor’s 500. Competitively, Strongbridge Biopharma plc’s 19.00% volatility makes it less volatile than Standard & Poor’s 500, because of the 0.81 beta.

Liquidity

The Current Ratio and Quick Ratio of Agios Pharmaceuticals Inc. are 6.9 and 6.9 respectively. Its competitor Strongbridge Biopharma plc’s Current Ratio is 5.2 and its Quick Ratio is 5. Agios Pharmaceuticals Inc. can pay off short and long-term obligations better than Strongbridge Biopharma plc.

Institutional and Insider Ownership

The shares of both Agios Pharmaceuticals Inc. and Strongbridge Biopharma plc are owned by institutional investors at 0% and 66.4% respectively. Insiders held roughly 0.3% of Agios Pharmaceuticals Inc.’s shares. Comparatively, insiders own roughly 0.8% of Strongbridge Biopharma plc’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Agios Pharmaceuticals Inc. 2.49% -2.96% -9.55% -6.82% -43.99% 4.34%
Strongbridge Biopharma plc 0% -23.08% -31.4% -45.15% -43.48% -41.96%

For the past year Agios Pharmaceuticals Inc. has 4.34% stronger performance while Strongbridge Biopharma plc has -41.96% weaker performance.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. The company is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors; and AG-348, a small molecule potent activator that is in Phase 2 clinical trial for the treatment of pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States, Sweden, and Cayman Islands. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. It is also involved in developing Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical development for the treatment of endogenous CushingÂ’s syndrome; and Veldoreotide, a novel somatostatin analogue that is in Phase II clinical development to treat acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.